Rockwell Medical (NASDAQ:RMTI – Get Free Report) and Senestech (NASDAQ:SNES – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.
Risk and Volatility
Rockwell Medical has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Senestech has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.
Insider & Institutional Ownership
23.3% of Rockwell Medical shares are owned by institutional investors. Comparatively, 5.2% of Senestech shares are owned by institutional investors. 3.6% of Rockwell Medical shares are owned by company insiders. Comparatively, 5.3% of Senestech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Rockwell Medical | 1 | 0 | 1 | 0 | 2.00 |
| Senestech | 1 | 1 | 0 | 1 | 2.33 |
Rockwell Medical currently has a consensus price target of $2.50, indicating a potential upside of 135.85%. Given Rockwell Medical’s higher possible upside, equities analysts clearly believe Rockwell Medical is more favorable than Senestech.
Profitability
This table compares Rockwell Medical and Senestech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Rockwell Medical | -7.30% | -16.77% | -9.88% |
| Senestech | -253.54% | -98.35% | -73.17% |
Valuation & Earnings
This table compares Rockwell Medical and Senestech”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Rockwell Medical | $75.58 million | 0.55 | -$480,000.00 | ($0.16) | -6.63 |
| Senestech | $1.86 million | 5.25 | -$6.18 million | ($3.65) | -0.51 |
Rockwell Medical has higher revenue and earnings than Senestech. Rockwell Medical is trading at a lower price-to-earnings ratio than Senestech, indicating that it is currently the more affordable of the two stocks.
Summary
Rockwell Medical beats Senestech on 10 of the 15 factors compared between the two stocks.
About Rockwell Medical
Rockwell Medical, Inc., together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including testing supplies, 5% acetic acid cleaning solution, 5% and 2% citric acid descaler, filtration salts, and other items used by hemodialysis providers. The company's hemodialysis concentrate products are used to sustain patient's life by removing toxins and balancing electrolytes in a dialysis patient's bloodstream. The company serves to hemodialysis clinics. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.
About Senestech
SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.
